Tharimmune Inc. has announced a private placement agreement with accredited individual and institutional investors to raise approximately $2.5 million. The company will issue 1,551,351 shares of common stock, pre-funded warrants for 137,838 shares, Series A warrants for 1,689,189 shares at $1.29 per share, and Series B warrants for 844,572 shares at $3.00 per share. The transaction, expected to close on June 20, 2025, pending customary conditions, will see President Street Global acting as the exclusive placement agent. The funds will support Tharimmune's clinical development and working capital needs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.